ClinicalTrials.gg
RecruitingNCT05058183Safe-DeUpdated Oct 29, 2026

Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer

An interventional study of ctDNA in Breast Cancer, sponsored by Royal Marsden NHS Foundation Trust. Recruiting at 13 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Royal Marsden NHS Foundation Trust · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.
Updated Oct 29, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
800
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust — 5 open to participants now, 9 under way, none of them phase 3. Breast Neoplasms · Royal Marsden NHS Foundation Trust.

Planned enrollment
4th of 24
800 · median 62
Started
2023
the only one that year
No phase
15 of 42
1 open now
Registered
35th of 42
by date

Among the 42 studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust, this one is the 4th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2023, is one of 15 with no phase, and was the 35th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 42 studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Breast Neoplasms by Royal Marsden NHS Foundation Trust, or all of them as a file.
02

Study summary

The SAFE-DE study investigates whether circulating tumour DNA (ctDNA) testing can guide adjuvant treatment decisions in patients with stage I breast cancer, identifying those who may be able to avoid chemotherapy after surgery. The study includes patients with stage I HER2-positive breast cancer and patients with stage I triple-negative breast cancer (TNBC) with high levels of tumour-infiltrating lymphocytes (TILs). The Signatera personalised ctDNA assay is used to detect molecular residual disease (MRD), which may indicate that cancer remains in the body after surgery.

SAFE-DE comprises two parts. Part A, which is closed to recruitment, investigated the incidence of post-operative ctDNA detection and its association with subsequent outcomes, including the potential prognostic significance of pre-operative ctDNA. Part B builds on this work by prospectively evaluating whether ctDNA-guided treatment and surveillance can reduce the use of adjuvant chemotherapy while maintaining favourable cancer outcomes.

Patients may be enrolled before surgery to facilitate pre-operative sampling and timely post-operative testing. Blood samples will be collected after surgery, including at 2 and 4 weeks. The results of the 2- and 4-week post-operative ctDNA tests will be shared with patients and their treating clinicians to inform treatment decisions in accordance with the study protocol and individual clinical circumstances. Pre-operative ctDNA results will be investigated as an exploratory measure and will not be disclosed for treatment decisions.

Patients with detectable ctDNA after surgery will be recommended standard adjuvant systemic treatment. Patients with no detectable ctDNA at both 2 and 4 weeks after surgery will be recommended not to receive adjuvant chemotherapy and will instead enter a ctDNA surveillance programme. If ctDNA becomes detectable during surveillance, patients will then be offered standard adjuvant treatment.

The primary purpose of Part B is to assess whether patients with undetectable ctDNA following surgery can remain free from distant recurrence without adjuvant chemotherapy. Additional outcomes include recurrence and survival, adjuvant treatment use, ctDNA detection during surveillance, quality of life and the cost-effectiveness of ctDNA-guided treatment.

Read the detailed description

Patients with stage I breast cancer generally have a favourable prognosis following surgery. However, patients with stage I HER2-positive breast cancer and triple-negative breast cancer (TNBC) remain at risk of recurrence and are commonly offered adjuvant systemic treatment following surgery. Although shorter chemotherapy regimens are used to reduce treatment-related morbidity, some patients may remain disease-free without chemotherapy, while others have residual cancer after surgery and remain at risk of recurrence despite treatment. Identifying patients who can safely avoid adjuvant chemotherapy, while ensuring that those at increased risk receive appropriate treatment, remains an important clinical challenge.

Circulating tumour DNA (ctDNA) provides a potential means of detecting molecular residual disease (MRD), which refers to cancer that remains in the body following treatment but may not be detectable using conventional clinical assessments. As tumour cells proliferate and die, tumour-derived DNA can be released into the circulation. Sequencing a patient's tumour to identify tumour-specific alterations enables highly sensitive analysis of plasma DNA for these alterations. Detection of ctDNA following potentially curative treatment is associated with an increased risk of subsequent disease recurrence.

The SAFE-DE study uses the Signatera personalised ctDNA assay to investigate the role of ctDNA testing in patients with stage I HER2-positive breast cancer and stage I TNBC with high levels of tumour-infiltrating lymphocytes (TILs). The study comprises two parts.

Part A, which is closed to recruitment, investigated the incidence of ctDNA detection in patients with stage I HER2-positive and triple-negative breast cancer following surgery. Its purpose was to identify patients with evidence of molecular residual disease and investigate the association between ctDNA detection and subsequent outcomes. The study also explored pre-operative ctDNA detection as a potential prognostic measure. Pre-operative results were not disclosed to patients or treating clinicians for treatment decisions because their clinical significance was less established than that of post-operative ctDNA detection.

Part A provided the foundation for the next stage of the study by investigating the use of ctDNA testing to identify patients who may be at increased risk of recurrence following surgery.

Part B builds on Part A by prospectively evaluating whether post-operative ctDNA results can be used to guide adjuvant treatment decisions, with the aim of reducing unnecessary chemotherapy while maintaining favourable cancer outcomes.

Patients may be enrolled before surgery to facilitate collection of pre-operative samples and timely post-operative testing. Pre-operative ctDNA will be investigated as an exploratory measure, and results will not be made available to patients or their treating clinicians for treatment decisions.

Following surgery, blood samples will be collected for ctDNA testing, including at 2 and 4 weeks after surgery. The results of these post-operative tests will be shared with patients and their treating clinicians and used to guide treatment in accordance with the study protocol.

Patients with detectable ctDNA after surgery will receive standard adjuvant systemic treatment, reflecting the increased risk of recurrence associated with molecular residual disease.

Patients with no detectable ctDNA at both 2 and 4 weeks after surgery will be recommended not to receive adjuvant chemotherapy and will instead enter a ctDNA surveillance programme. Serial blood testing during follow-up will allow the study to assess whether ctDNA remains undetectable or becomes detectable over time. If ctDNA becomes detectable during surveillance, patients will be offered standard adjuvant treatment.

The primary purpose of Part B is to determine whether patients with undetectable ctDNA following surgery can remain free from distant recurrence without receiving adjuvant chemotherapy. The study will also assess other measures of recurrence and survival, patterns of anticancer treatment use, ctDNA detection during surveillance, quality of life and the cost-effectiveness of using ctDNA to guide treatment decisions.

By evaluating a ctDNA-guided treatment and surveillance strategy, SAFE-DE aims to provide further evidence on whether molecular residual disease testing can support more personalised management of early breast cancer, reducing exposure to chemotherapy in selected patients while identifying those who may require additional treatment.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older
  2. (ECOG) performance status of 0,1 or 2
  3. Have an estimated of at least 5 years
  4. confirmed breast cancer that is either:

    (A) -positive as defined by 2023 ASCO-CAP guidelines determined by local testing* or (B) Triple negative defined as ER negative (ER staining in \<1% tumour cells or ER Allred score \<3/8) and PR negative (PR staining in \<10% tumour cells or PR Allred score \<6/8) and HER2-negative by 2023 ASCO-CAP guidelines determined by local testing. Patients without PR testing results may enrol on the basis of ER and HER2 results.

    * Note: Patients negative for ER and PR may enrol whilst awaiting HER2 testing results

  5. Pathological stage 1 cancer as below: **

    EITHER

    1. HER2-positive invasive tumour size 5-20mm OR
    2. TNBC invasive tumour size 5-20mm, with high TILs (stromal tumour infiltration lymphocytes >30%) determined by central testing

    AND (c) Node negative (isolated tumour cells are allowed)

    **Patients may be enrolled pre-operatively with clinical stage 1 cancer with primary tumour size on imaging 5-20mm and a normal axilla ultrasound or a negative axilla. Patients enrolled before surgery will only continue in study after surgery when confirmed pathological stage 1

  6. Planned for and fit enough to receive standard post-operative chemotherapy, with HER2 targeting as appropriate, in the opinion of the investigator
  7. Able and willing to provide written or remote consent
  8. Negative serum pregnancy test at screening (females of ). Patients able to have children are advised to use a method of , or abstinence, throughout the ctDNA surveillance period
  9. Willing and able to comply with scheduled visits, laboratory tests and other procedures
  10. Available tissue from breast surgery or diagnostic core (preference to diagnostic core for rapidity of tissue sequencing).

Exclusion criteria

Exclusion criteria:

  1. Prior treatment for the current breast cancer, other than surgery if recruited post-operatively
  2. Multifocal invasive cancer
  3. Micrometastasis or macrometastasis in axillary lymph nodes
  4. pT1a invasive tumour size \<5mm
  5. Distant disease on imaging performed as part of standard of care
  6. Planned participation in an alternative treatment trial
  7. Diagnosis of alternative cancer within the last 5 years except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or cervix
  8. Known or AIDS-related illness
  9. Known positive or test indicating acute or chronic infection
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    All participants

    All participants

    Diagnostic Test: ctDNA

Interventions

  • Diagnostic testctDNA

    Patients with stage 1 HER2-positive breast cancer or stage 1 triple-negative breast cancer (TNBC) with high tumour infiltrating lymphocytes (TILs) will have access to the Signatera genome ctDNA assay alongside standard clinical care. Patients will preferably be enrolled prior to surgery and will have ctDNA testing before and after surgery. The pre-surgery ctDNA result will not be made available to patients or their treating clinicians. Post-surgery ctDNA results will be made available to treating clinicians and will be used to inform clinical decision-making regarding adjuvant systemic treatment. Patients with undetectable ctDNA after surgery may be managed without adjuvant chemotherapy and will undergo further ctDNA surveillance instead. Patients with detectable ctDNA after surgery, who are considered to have a higher risk of relapse, will not enter the surveillance population in which adjuvant systemic treatment is omitted.

06

What researchers measure

Primary outcomes

  1. Distant recurrence-free interval in patients with undetectable post-surgery ctDNA

    The time from the date of surgery to the first recorded event of distant recurrence or death from breast cancer. This will be evaluated in patients who proceed to surgery and have at least one undetectable ctDNA result at either 2 and/or 4 weeks post-surgery, with no detected ctDNA result at either post-surgery timepoint. Patients without a recorded event will be censored at the first occurrence of death from another cause, complete withdrawal from trial follow-up, or diagnosis of a new primary cancer. This will be assessed separately in patients with stage 1 HER2-positive breast cancer and patients with stage 1 TNBC with high tumour infiltrating lymphocytes (TILs).

    Time frame: From the date of surgery until first documented event, assessed up to 10 years.

Secondary outcomes

  1. Distant recurrence-free interval in all patients

    The time from the date of surgery to the first recorded event of distant recurrence or death from breast cancer, evaluated in all patients who proceed to surgery regardless of their ctDNA status at 2 and 4 weeks post-surgery. Results will be reported in the HER2-positive cohort, TNBC cohort, and both cohorts combined.

    Time frame: From the date of surgery until first documented event, assessed up to 10 years.

  2. Invasive disease-free survival (IDFS)

    The time from the date of surgery to the first occurrence of an invasive ipsilateral breast tumour recurrence, local/regional invasive recurrence, distant recurrence, death from breast cancer, death from another cause, death from an unknown cause, invasive contralateral breast cancer, or a second primary invasive cancer (non-breast). This will be evaluated in patients with undetectable ctDNA MRD following surgery.

    Time frame: From the date of surgery until first documented event, assessed up to 10 years.

  3. Recurrence-free interval (RFI)

    The time from the date of surgery to the first occurrence of an invasive ipsilateral breast tumour recurrence, local/regional invasive recurrence, distant recurrence, or death from breast cancer. This will be evaluated in patients with undetectable ctDNA MRD following surgery.

    Time frame: From the date of surgery until first documented event, assessed up to 10 years.

  4. Distant recurrence-free survival (DRFS)

    The time from the date of surgery to the first occurrence of distant recurrence or death from breast cancer. This will be evaluated in patients with undetectable ctDNA MRD following surgery.

    Time frame: From the date of surgery until first documented event, assessed up to 10 years.

  5. Breast cancer-specific survival (BCSS)

    The time from the date of surgery to death from breast cancer. This will be evaluated in patients with undetectable ctDNA MRD following surgery.

    Time frame: From the date of surgery until documented date of death from breast cancer, assessed up to 10 years.

  6. Overall survival (OS)

    The time from the date of surgery to death from any cause. This will be evaluated in patients with undetectable ctDNA MRD following surgery.

    Time frame: From the date of surgery until date of death, assessed up to 10 years.

07

Study locations

13 of 13 sites recruiting
08

References and documents

Publications

  • Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Gronroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium; Swanton C. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. PubMed 28445469 ↗
  • Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, Ali S, Cleator S, Kenny L, Stebbing J, Rutherford M, Sethi H, Boydell A, Swenerton R, Fernandez-Garcia D, Gleason KLT, Goddard K, Guttery DS, Assaf ZJ, Wu HT, Natarajan P, Moore DA, Primrose L, Dashner S, Tin AS, Balcioglu M, Srinivasan R, Shchegrova SV, Olson A, Hafez D, Billings P, Aleshin A, Rehman F, Toghill BJ, Hills A, Louie MC, Lin CJ, Zimmermann BG, Shaw JA. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin Cancer Res. 2019 Jul 15;25(14):4255-4263. doi: 10.1158/1078-0432.CCR-18-3663. Epub 2019 Apr 16. PubMed 30992300 ↗
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012 Feb 4;379(9814):432-44. doi: 10.1016/S0140-6736(11)61625-5. Epub 2011 Dec 5. PubMed 22152853 ↗
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 May 14-20;365(9472):1687-717. doi: 10.1016/S0140-6736(05)66544-0. PubMed 15894097 ↗
  • Garcia-Murillas I, Chopra N, Comino-Mendez I, Beaney M, Tovey H, Cutts RJ, Swift C, Kriplani D, Afentakis M, Hrebien S, Walsh-Crestani G, Barry P, Johnston SRD, Ring A, Bliss J, Russell S, Evans A, Skene A, Wheatley D, Dowsett M, Smith IE, Turner NC. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncol. 2019 Oct 1;5(10):1473-1478. doi: 10.1001/jamaoncol.2019.1838. PubMed 31369045 ↗
  • Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021. PubMed 26311728 ↗
  • Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol. 2009 Mar 10;27(8):1177-83. doi: 10.1200/JCO.2008.18.4028. Epub 2009 Feb 9. PubMed 19204201 ↗
  • Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE Jr. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018 Apr;19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6. Epub 2018 Feb 28. PubMed 29501363 ↗
  • Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS, Heilskov Rasmussen M, Vang S, Shchegrova S, Frydendahl Boll Johansen A, Srinivasan R, Assaf Z, Balcioglu M, Olson A, Dashner S, Hafez D, Navarro S, Goel S, Rabinowitz M, Billings P, Sigurjonsson S, Dyrskjot L, Swenerton R, Aleshin A, Laurberg S, Husted Madsen A, Kannerup AS, Stribolt K, Palmelund Krag S, Iversen LH, Gotschalck Sunesen K, Lin CJ, Zimmermann BG, Lindbjerg Andersen C. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019 Aug 1;5(8):1124-1131. doi: 10.1001/jamaoncol.2019.0528. PubMed 31070691 ↗
  • Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, Tacey M, Wong HL, Christie M, Kosmider S, Skinner I, Wong R, Steel M, Tran B, Desai J, Jones I, Haydon A, Hayes T, Price TJ, Strausberg RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016 Jul 6;8(346):346ra92. doi: 10.1126/scitranslmed.aaf6219. PubMed 27384348 ↗
  • Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 8;372(2):134-41. doi: 10.1056/NEJMoa1406281. PubMed 25564897 ↗
  • Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 Aug 1;37(22):1868-1875. doi: 10.1200/JCO.19.00066. Epub 2019 Apr 2. PubMed 30939096 ↗
  • von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. PubMed 28581356 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jan 2038, 174 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 174 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Dec 2025 → Jan 2038 and completion Dec 2028 → Jan 2038.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2021
First posted
Sep 27, 2021
StartActual
Jun 5, 2023
Primary completionEst.
Jan 1, 2038was Dec 2025
CompletionEst.
Jan 1, 2038was Dec 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added
Show 11 added (11 United Kingdom)
  • Royal Cornwall Hospitals NHS Trust · Truro, United Kingdom
  • Royal Bournemouth Hospital · Bournemouth, United Kingdom
  • The Clatterbridge Cancer Centre · Liverpool, United Kingdom
  • Whittington Hospital · London, United Kingdom
  • University College London Hospital · London, United Kingdom
  • The Royal Free Hospital · London, United Kingdom
  • Barts Health NHS Trust · London, United Kingdom
  • The Christie NHS Foundation Trust · Manchester, United Kingdom
  • Nottingham University Hospitals NHS Trust, City Hospital Campus · Nottingham, United Kingdom
  • University Hospitals Dorset: Poole Hospital · Poole, United Kingdom
  • The Royal Albert Edward Infirmary · Wigan, United Kingdom
Oct 29, 2026
Primary completion
Dec 5, 2025→Jan 1, 2038
Oct 29, 2026
Study completion
Dec 5, 2028→Jan 1, 2038
Oct 29, 2026
Enrollment
400→800
Oct 29, 2026
Eligibility
6 inclusion criteria edited, 10 added, 7 removed; 8 exclusion criteria added, 4 removed
What changed in the criteria
Inclusion criteria
  • AddedEastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2
  • AddedHave an estimated life expectancy of at least 5 years
  • EditedPatients with histologicallyHistologically confirmed breast cancer that is either:
  • EditedHER2 -positive as defined by 20182023 ASCO-CAP guidelines determined by local testing * or (B) Triple negative defined as ER negative (ER staining in <1% tumour cells or ER Allred score <3/8) and PR negative (PR staining in <10% tumour cells or PR Allred score <6/8) and HER2 -negative by 20182023 ASCO-CAP guidelines determined by local testing. Patients without PR testing results may enrol on the basis of ER and HER2 results.
  • Edited* Note that patients: Patients negative for ER and PR may enrol whilst awaiting HER2 testing results
  • EditedStagePathological stage 1 cancer excluding pT1aN0 cancer, defined asas below: **
  • AddedEITHER
  • AddedHER2-positive invasive tumour size 5-20mm OR
  • AddedTNBC invasive tumour size 5-20mm, with high TILs (stromal tumour infiltration lymphocytes >30%) determined by central testing
  • AddedAND (c) Node negative (isolated tumour cells are allowed)
  • Edited**Patients prior to surgerymay be enrolled pre-operatively with clinical stage 1 cancer with primary tumour size on imaging 65-20mm and a normal axilla ultrasound or a biopsy negative axilla. Patients enrolled before surgery will only continue in study after surgery when confirmed pathological stage 1
  • RemovedPatients who enrol prior to surgery will only continue further testing in the trial if their pathological staging fits the after surgery criteria.
  • RemovedPatients after surgery with either
  • RemovedPrimary tumour size pT1b or pT1c (6-20mm) and pN0 or pN1mi (micrometastasis).
  • RemovedPrimary tumour size pT1a (1-5mm) and pN1mi
  • RemovedNote that patients consenting after surgery may not enrol with pT1aN0 stage disease
  • RemovedPatients should consent prior to surgery (preferred) or within 2 weeks of surgery. Patients who consent after surgery may extend consent to 4 weeks after surgery, although this will delay the receipt of ctDNA results.
  • EditedPlanned for and fit enough to receive full standard post-operative chemotherapy, with HER2 targeting as appropriate., in the opinion of the investigator
  • RemovedAbility to give informed consent and comply with study procedures including blood tests and follow-up for five years.
  • AddedAble and willing to provide written informed consent or remote consent
  • AddedNegative serum pregnancy test at screening (females of childbearing potential). Patients able to have children are advised to use a method of contraception, or abstinence, throughout the ctDNA surveillance period
  • AddedWilling and able to comply with scheduled visits, laboratory tests and other procedures
  • AddedAvailable tissue from breast surgery or diagnostic core (preference to diagnostic core for rapidity of tissue sequencing).
Exclusion criteria
  • RemovedDistant metastatic disease.
  • AddedPrior treatment for the current breast cancer, other than surgery if recruited post-operatively
  • RemovedDiagnosis of alternative cancer within the last 5 years other than resected non-melanoma skin cancer or cervical intraepithelial neoplasia.
  • RemovedAny prior treatment (including neo-adjuvant chemotherapy) for the current breast cancer with the exception of surgical resection for patients enrolling after surgery.
  • RemovedKnown HIV or hepatitis B or hepatitis C infection.
  • AddedMicrometastasis or macrometastasis in axillary lymph nodes
  • AddedpT1a invasive tumour size <5mm
  • AddedDistant metastatic disease on imaging performed as part of standard of care
  • AddedPlanned participation in an alternative treatment trial
  • AddedDiagnosis of alternative cancer within the last 5 years except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or cervix
  • AddedKnown HIV or AIDS-related illness
  • AddedKnown positive HBV or HCV test indicating acute or chronic infection
Oct 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Incidence of patients with ctDNA detection treated with surgery for stage 1 breast cancerNow Distant recurrence-free interval in patients with undetectable post-surgery ctDNATime frame: 2 to 4 weeks post surgery. → From the date of surgery until first documented event, assessed up to 10 years.
Oct 29, 2026
Secondary outcomes
3 edited, 3 added, 2 removed
What changed in the outcomes
  • EditedDistant recurrence -free survivalinterval in all patientsTime frame: Through study completion, minimum 5 years unless early study termination. → From the date of surgery until first documented event, assessed up to 10 years.
  • EditedInvasive disease -free survival (IDFS)Time frame: Through study completion, minimum 5 years unless early study termination. → From the date of surgery until first documented event, assessed up to 10 years.
  • EditedOverall survival (OS)Time frame: Through study completion, minimum 5 years unless early study termination. → From the date of surgery until date of death, assessed up to 10 years.
  • AddedRecurrence-free interval (RFI)Time frame: From the date of surgery until first documented event, assessed up to 10 years.
  • AddedDistant recurrence-free survival (DRFS)Time frame: From the date of surgery until first documented event, assessed up to 10 years.
  • AddedBreast cancer-specific survival (BCSS)Time frame: From the date of surgery until documented date of death from breast cancer, assessed up to 10 years.
  • RemovedRelapse free survivalTime frame: Through study completion, minimum 5 years unless early study termination.
  • RemovedProportion of physicians who change treatment adviceTime frame: Up to 6 weeks post surgery.
Oct 29, 2026
Sponsor
Collaborators added: Institute of Cancer Research, United Kingdom; collaborators removed: Massachusetts General Hospital
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    11 sites added
    Show 11 added (11 United Kingdom)
    • Royal Cornwall Hospitals NHS Trust · Truro, United Kingdom
    • Royal Bournemouth Hospital · Bournemouth, United Kingdom
    • The Clatterbridge Cancer Centre · Liverpool, United Kingdom
    • Whittington Hospital · London, United Kingdom
    • University College London Hospital · London, United Kingdom
    • The Royal Free Hospital · London, United Kingdom
    • Barts Health NHS Trust · London, United Kingdom
    • The Christie NHS Foundation Trust · Manchester, United Kingdom
    • Nottingham University Hospitals NHS Trust, City Hospital Campus · Nottingham, United Kingdom
    • University Hospitals Dorset: Poole Hospital · Poole, United Kingdom
    • The Royal Albert Edward Infirmary · Wigan, United Kingdom
    Primary completion Dec 5, 2025→Jan 1, 2038
    Study completion Dec 5, 2028→Jan 1, 2038
    Enrollment 400→800
    Eligibility 6 inclusion criteria edited, 10 added, 7 removed; 8 exclusion criteria added, 4 removed
    What changed in the criteria
    Inclusion criteria
    • AddedEastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2
    • AddedHave an estimated life expectancy of at least 5 years
    • EditedPatients with histologicallyHistologically confirmed breast cancer that is either:
    • EditedHER2 -positive as defined by 20182023 ASCO-CAP guidelines determined by local testing * or (B) Triple negative defined as ER negative (ER staining in <1% tumour cells or ER Allred score <3/8) and PR negative (PR staining in <10% tumour cells or PR Allred score <6/8) and HER2 -negative by 20182023 ASCO-CAP guidelines determined by local testing. Patients without PR testing results may enrol on the basis of ER and HER2 results.
    • Edited* Note that patients: Patients negative for ER and PR may enrol whilst awaiting HER2 testing results
    • EditedStagePathological stage 1 cancer excluding pT1aN0 cancer, defined asas below: **
    • AddedEITHER
    • AddedHER2-positive invasive tumour size 5-20mm OR
    • AddedTNBC invasive tumour size 5-20mm, with high TILs (stromal tumour infiltration lymphocytes >30%) determined by central testing
    • AddedAND (c) Node negative (isolated tumour cells are allowed)
    • Edited**Patients prior to surgerymay be enrolled pre-operatively with clinical stage 1 cancer with primary tumour size on imaging 65-20mm and a normal axilla ultrasound or a biopsy negative axilla. Patients enrolled before surgery will only continue in study after surgery when confirmed pathological stage 1
    • RemovedPatients who enrol prior to surgery will only continue further testing in the trial if their pathological staging fits the after surgery criteria.
    • RemovedPatients after surgery with either
    • RemovedPrimary tumour size pT1b or pT1c (6-20mm) and pN0 or pN1mi (micrometastasis).
    • RemovedPrimary tumour size pT1a (1-5mm) and pN1mi
    • RemovedNote that patients consenting after surgery may not enrol with pT1aN0 stage disease
    • RemovedPatients should consent prior to surgery (preferred) or within 2 weeks of surgery. Patients who consent after surgery may extend consent to 4 weeks after surgery, although this will delay the receipt of ctDNA results.
    • EditedPlanned for and fit enough to receive full standard post-operative chemotherapy, with HER2 targeting as appropriate., in the opinion of the investigator
    • RemovedAbility to give informed consent and comply with study procedures including blood tests and follow-up for five years.
    • AddedAble and willing to provide written informed consent or remote consent
    • AddedNegative serum pregnancy test at screening (females of childbearing potential). Patients able to have children are advised to use a method of contraception, or abstinence, throughout the ctDNA surveillance period
    • AddedWilling and able to comply with scheduled visits, laboratory tests and other procedures
    • AddedAvailable tissue from breast surgery or diagnostic core (preference to diagnostic core for rapidity of tissue sequencing).
    Exclusion criteria
    • RemovedDistant metastatic disease.
    • AddedPrior treatment for the current breast cancer, other than surgery if recruited post-operatively
    • RemovedDiagnosis of alternative cancer within the last 5 years other than resected non-melanoma skin cancer or cervical intraepithelial neoplasia.
    • RemovedAny prior treatment (including neo-adjuvant chemotherapy) for the current breast cancer with the exception of surgical resection for patients enrolling after surgery.
    • RemovedKnown HIV or hepatitis B or hepatitis C infection.
    • AddedMicrometastasis or macrometastasis in axillary lymph nodes
    • AddedpT1a invasive tumour size <5mm
    • AddedDistant metastatic disease on imaging performed as part of standard of care
    • AddedPlanned participation in an alternative treatment trial
    • AddedDiagnosis of alternative cancer within the last 5 years except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or cervix
    • AddedKnown HIV or AIDS-related illness
    • AddedKnown positive HBV or HCV test indicating acute or chronic infection
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Incidence of patients with ctDNA detection treated with surgery for stage 1 breast cancerNow Distant recurrence-free interval in patients with undetectable post-surgery ctDNATime frame: 2 to 4 weeks post surgery. → From the date of surgery until first documented event, assessed up to 10 years.
    Secondary outcomes 3 edited, 3 added, 2 removed
    What changed in the outcomes
    • EditedDistant recurrence -free survivalinterval in all patientsTime frame: Through study completion, minimum 5 years unless early study termination. → From the date of surgery until first documented event, assessed up to 10 years.
    • EditedInvasive disease -free survival (IDFS)Time frame: Through study completion, minimum 5 years unless early study termination. → From the date of surgery until first documented event, assessed up to 10 years.
    • EditedOverall survival (OS)Time frame: Through study completion, minimum 5 years unless early study termination. → From the date of surgery until date of death, assessed up to 10 years.
    • AddedRecurrence-free interval (RFI)Time frame: From the date of surgery until first documented event, assessed up to 10 years.
    • AddedDistant recurrence-free survival (DRFS)Time frame: From the date of surgery until first documented event, assessed up to 10 years.
    • AddedBreast cancer-specific survival (BCSS)Time frame: From the date of surgery until documented date of death from breast cancer, assessed up to 10 years.
    • RemovedRelapse free survivalTime frame: Through study completion, minimum 5 years unless early study termination.
    • RemovedProportion of physicians who change treatment adviceTime frame: Up to 6 weeks post surgery.
    Sponsor Collaborators added: Institute of Cancer Research, United Kingdom; collaborators removed: Massachusetts General Hospital
    + 5 other changes: index terms, verification date, description, arm descriptions and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05058183
Responsible party
Sponsor
First posted
Sep 27, 2021
Start date
Jun 5, 2023
Primary completion
Jan 1, 2038 (estimated)
Completion
Jan 1, 2038 (estimated)
Last update
Oct 29, 2026

Study contacts

Project Manager
Contact
SAFE-DE@rmh.nhs.uk
020 7808 2887
Nicholas Turner
principal investigator · Royal Marsden NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion